Carcinomatosis — Variants & evidence

Carcinomatosis — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items (3 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GNAS Mutation1
Palbociclib	Pseudomyxoma Peritonei	Predictive	B	Supports Sensitivity Response	3	accepted	EID13146 This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC) PMID 39413348 · Weitz et al., 2025 · Open in CIViC	civic
GNAS R2011
(prognostic)	Pseudomyxoma Peritonei	Prognostic	B	Supports Poor Outcome	3	accepted	EID1994 Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC) PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC	civic
KRAS Mutation1
(prognostic)	Pseudomyxoma Peritonei	Prognostic	B	Supports Poor Outcome	3	accepted	EID1596 40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC) PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC	civic

Data updated 9 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.